Does Hypervascularity of Liver Metastases as Detected on MRI Predict Discase Progression in Breast Cancer Patients?

Larissa Braga, Richard C. Semelka, Ricardo Pietrobon, Diego R Martin, Nestor De Barros, Ulrich Guller

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

OBJECTIVE. The aim of our study was to evaluate the association of the vascularity of liver metastases, as characterized by MRI, and disease progression in breast cancer patients. MATERIALS AND METHODS. Sixteen breast cancer patients with liver metastases who underwent MRI before and after systemic therapy were retrospectively identified. On the basis of comparison of each MRI examination with the previous examination, disease status of the patients was classified as complete response, partial response, stable disease, or progressive disease. Liver metastases were characterized as hyper- or hypovascular on the basis of the degree of enhancement in the arterial, portal, and interstitial phases of imaging after administration of a contrast agent. Fisher's exact test and ordinal logistic regression models, including the type of systemic therapy, presence of multiple metastases, and hormone receptor status, were used to estimate the unadjusted and risk-adjusted association between the presence of hypervascular liver metastases and disease progression. RESULTS. All patients in our sample (n = 16) were women and most (12/16, 75%) were white. Their median age was 51.5 years. In unadjusted analyses, the association between the presence of hypervascular liver metastases and disease progression was statistically significant (p < 0.0001). In multiple logistic regression analyses, hypervascular liver metastases were found to be an independent predictor of disease progression. Patients with hypervascular liver lesions were 20.5 times more likely to experience disease progression than patients without hypervascular metastases (odds ratio, 20.5; 95% confidence interval, 5.1-83.5; p < 0.0001). CONCLUSION. Our analysis provides suggestive evidence that disease progression can be predicted through MRI assessment of the vascularity of liver metastases in patients with breast cancer.

Original languageEnglish (US)
Pages (from-to)1207-1213
Number of pages7
JournalAmerican Journal of Roentgenology
Volume182
Issue number5
StatePublished - May 2004
Externally publishedYes

Fingerprint

Chymopapain
Breast Neoplasms
Neoplasm Metastasis
Disease Progression
Liver
Logistic Models
Liver Diseases
Contrast Media
Odds Ratio
Regression Analysis
Hormones
Confidence Intervals

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Does Hypervascularity of Liver Metastases as Detected on MRI Predict Discase Progression in Breast Cancer Patients? / Braga, Larissa; Semelka, Richard C.; Pietrobon, Ricardo; Martin, Diego R; De Barros, Nestor; Guller, Ulrich.

In: American Journal of Roentgenology, Vol. 182, No. 5, 05.2004, p. 1207-1213.

Research output: Contribution to journalArticle

Braga, Larissa ; Semelka, Richard C. ; Pietrobon, Ricardo ; Martin, Diego R ; De Barros, Nestor ; Guller, Ulrich. / Does Hypervascularity of Liver Metastases as Detected on MRI Predict Discase Progression in Breast Cancer Patients?. In: American Journal of Roentgenology. 2004 ; Vol. 182, No. 5. pp. 1207-1213.
@article{fdf0f962649d48ffb7f6c1d229dd65bc,
title = "Does Hypervascularity of Liver Metastases as Detected on MRI Predict Discase Progression in Breast Cancer Patients?",
abstract = "OBJECTIVE. The aim of our study was to evaluate the association of the vascularity of liver metastases, as characterized by MRI, and disease progression in breast cancer patients. MATERIALS AND METHODS. Sixteen breast cancer patients with liver metastases who underwent MRI before and after systemic therapy were retrospectively identified. On the basis of comparison of each MRI examination with the previous examination, disease status of the patients was classified as complete response, partial response, stable disease, or progressive disease. Liver metastases were characterized as hyper- or hypovascular on the basis of the degree of enhancement in the arterial, portal, and interstitial phases of imaging after administration of a contrast agent. Fisher's exact test and ordinal logistic regression models, including the type of systemic therapy, presence of multiple metastases, and hormone receptor status, were used to estimate the unadjusted and risk-adjusted association between the presence of hypervascular liver metastases and disease progression. RESULTS. All patients in our sample (n = 16) were women and most (12/16, 75{\%}) were white. Their median age was 51.5 years. In unadjusted analyses, the association between the presence of hypervascular liver metastases and disease progression was statistically significant (p < 0.0001). In multiple logistic regression analyses, hypervascular liver metastases were found to be an independent predictor of disease progression. Patients with hypervascular liver lesions were 20.5 times more likely to experience disease progression than patients without hypervascular metastases (odds ratio, 20.5; 95{\%} confidence interval, 5.1-83.5; p < 0.0001). CONCLUSION. Our analysis provides suggestive evidence that disease progression can be predicted through MRI assessment of the vascularity of liver metastases in patients with breast cancer.",
author = "Larissa Braga and Semelka, {Richard C.} and Ricardo Pietrobon and Martin, {Diego R} and {De Barros}, Nestor and Ulrich Guller",
year = "2004",
month = "5",
language = "English (US)",
volume = "182",
pages = "1207--1213",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

TY - JOUR

T1 - Does Hypervascularity of Liver Metastases as Detected on MRI Predict Discase Progression in Breast Cancer Patients?

AU - Braga, Larissa

AU - Semelka, Richard C.

AU - Pietrobon, Ricardo

AU - Martin, Diego R

AU - De Barros, Nestor

AU - Guller, Ulrich

PY - 2004/5

Y1 - 2004/5

N2 - OBJECTIVE. The aim of our study was to evaluate the association of the vascularity of liver metastases, as characterized by MRI, and disease progression in breast cancer patients. MATERIALS AND METHODS. Sixteen breast cancer patients with liver metastases who underwent MRI before and after systemic therapy were retrospectively identified. On the basis of comparison of each MRI examination with the previous examination, disease status of the patients was classified as complete response, partial response, stable disease, or progressive disease. Liver metastases were characterized as hyper- or hypovascular on the basis of the degree of enhancement in the arterial, portal, and interstitial phases of imaging after administration of a contrast agent. Fisher's exact test and ordinal logistic regression models, including the type of systemic therapy, presence of multiple metastases, and hormone receptor status, were used to estimate the unadjusted and risk-adjusted association between the presence of hypervascular liver metastases and disease progression. RESULTS. All patients in our sample (n = 16) were women and most (12/16, 75%) were white. Their median age was 51.5 years. In unadjusted analyses, the association between the presence of hypervascular liver metastases and disease progression was statistically significant (p < 0.0001). In multiple logistic regression analyses, hypervascular liver metastases were found to be an independent predictor of disease progression. Patients with hypervascular liver lesions were 20.5 times more likely to experience disease progression than patients without hypervascular metastases (odds ratio, 20.5; 95% confidence interval, 5.1-83.5; p < 0.0001). CONCLUSION. Our analysis provides suggestive evidence that disease progression can be predicted through MRI assessment of the vascularity of liver metastases in patients with breast cancer.

AB - OBJECTIVE. The aim of our study was to evaluate the association of the vascularity of liver metastases, as characterized by MRI, and disease progression in breast cancer patients. MATERIALS AND METHODS. Sixteen breast cancer patients with liver metastases who underwent MRI before and after systemic therapy were retrospectively identified. On the basis of comparison of each MRI examination with the previous examination, disease status of the patients was classified as complete response, partial response, stable disease, or progressive disease. Liver metastases were characterized as hyper- or hypovascular on the basis of the degree of enhancement in the arterial, portal, and interstitial phases of imaging after administration of a contrast agent. Fisher's exact test and ordinal logistic regression models, including the type of systemic therapy, presence of multiple metastases, and hormone receptor status, were used to estimate the unadjusted and risk-adjusted association between the presence of hypervascular liver metastases and disease progression. RESULTS. All patients in our sample (n = 16) were women and most (12/16, 75%) were white. Their median age was 51.5 years. In unadjusted analyses, the association between the presence of hypervascular liver metastases and disease progression was statistically significant (p < 0.0001). In multiple logistic regression analyses, hypervascular liver metastases were found to be an independent predictor of disease progression. Patients with hypervascular liver lesions were 20.5 times more likely to experience disease progression than patients without hypervascular metastases (odds ratio, 20.5; 95% confidence interval, 5.1-83.5; p < 0.0001). CONCLUSION. Our analysis provides suggestive evidence that disease progression can be predicted through MRI assessment of the vascularity of liver metastases in patients with breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=1942501552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1942501552&partnerID=8YFLogxK

M3 - Article

C2 - 15100120

AN - SCOPUS:1942501552

VL - 182

SP - 1207

EP - 1213

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -